|
PIK3R4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.61499702500123E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.45069997628633E-09 |
| Normal-vs-Stage2 |
9.987000E-04 |
| Normal-vs-Stage3 |
7.48578976583758E-12 |
| Normal-vs-Stage4 |
4.16879863962549E-11 |
| Stage1-vs-Stage2 |
3.176600E-01 |
| Stage1-vs-Stage3 |
3.240300E-02 |
| Stage1-vs-Stage4 |
3.819900E-03 |
| Stage2-vs-Stage3 |
4.021500E-02 |
| Stage2-vs-Stage4 |
9.982900E-03 |
| Stage3-vs-Stage4 |
3.599200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.4584782794318E-13 |
| Normal-vs-AfricanAmerican |
2.284000E-03 |
| Normal-vs-Asian |
2.87619999994604E-06 |
| Caucasian-vs-AfricanAmerican |
1.601150E-01 |
| Caucasian-vs-Asian |
5.741000E-01 |
| AfricanAmerican-vs-Asian |
4.217000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.74329448046728E-11 |
| Normal-vs-Female |
4.23790003090119E-10 |
| Male-vs-Female |
1.014190E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.30080000104726E-08 |
| Normal-vs-Age(41-60Yrs) |
2.67769995065947E-09 |
| Normal-vs-Age(61-80Yrs) |
1.05280006934549E-10 |
| Normal-vs-Age(81-100Yrs) |
4.584100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.075400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.251200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.470400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.267800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.765200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.816400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.00800000000179E-05 |
| Classical-VS-Follicular |
9.260200E-01 |
| Classical-VS-Other |
7.238300E-02 |
| Classical-VS-Normal |
1.92240001695154E-09 |
| Tall-VS-Follicular |
1.164850E-03 |
| Tall-VS-Other |
7.580600E-01 |
| Tall-VS-Normal |
4.4202419502426E-12 |
| Follicular-VS-Other |
1.196180E-01 |
| Follicular-VS-Normal |
1.67740000001082E-06 |
| Other-VS-Normal |
2.011300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.16470000310898E-08 |
| Normal-vs-N1 |
2.85219625695277E-11 |
| N0-vs-N1 |
1.554110E-02 |
|
|
